Management of Spasticity, Pain, and Paroxysmal Phenomena in Multiple Sclerosis

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2002 Mar 20

PMID 11898533

Citations 4

Authors

R T Schapiro

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is a disease with tremendous variability and innumerable symptoms. Among the more common symptoms is spasticity. Despite a lack of full knowledge of the physiology causing this phenomenon, successful treatments have been developed. Many of these have had a recent introduction. Pain and paroxysmal phenomena are surprisingly common in MS, but have not had the recognition their frequency deserves. It is not unusual to hear that they are rare in MS, but surprisingly they are all too common. Their management is changing as newer treatments are developed.

Citing Articles

A comprehensive two-sample Mendelian randomization analysis of trigeminal neuralgia and modifiable risk factors.

Wei X, Zhou H, Zhang S, Hu X, Wei Z, Li Y Front Neurol. 2023; 14:1292958.

PMID: 38073645 PMC: 10703362. DOI: 10.3389/fneur.2023.1292958.

Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Berkovich R, Agius M Ther Adv Neurol Disord. 2014; 7(2):83-96.

PMID: 24587825 PMC: 3932770. DOI: 10.1177/1756285613518599.

Current management of pain associated with multiple sclerosis.

Pollmann W, Feneberg W CNS Drugs. 2008; 22(4):291-324.

PMID: 18336059 DOI: 10.2165/00023210-200822040-00003.

A benefit-risk assessment of baclofen in severe spinal spasticity.

Dario A, Tomei G Drug Saf. 2004; 27(11):799-818.

PMID: 15350152 DOI: 10.2165/00002018-200427110-00004.

References

Brodeur C, Montplaisir J, Godbout R, MARINIER R . Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology. 1988; 38(12):1845-8. DOI: 10.1212/wnl.38.12.1845. View

Evidente V, Adler C, Caviness J, Hentz J, Gwinn-Hardy K . Amantadine is beneficial in restless legs syndrome. Mov Disord. 2000; 15(2):324-7. DOI: 10.1002/1531-8257(200003)15:2<324::aid-mds1020>3.0.co;2-4. View

Filloux F . Neuropathophysiology of movement disorders in cerebral palsy. J Child Neurol. 1996; 11 Suppl 1:S5-12. DOI: 10.1177/0883073896011001S02. View

Postert T, McMonagle U, Buttner T, Pohlau D, Meves S, Przuntek H . Paroxysmal convergence spasm in multiple sclerosis. Acta Neurol Scand. 1996; 94(1):35-7. DOI: 10.1111/j.1600-0404.1996.tb00036.x. View

Ezra E, Plant G . Paroxysmal superior rectus and levator palpebrae spasm: a unique presentation of multiple sclerosis. Br J Ophthalmol. 1996; 80(2):187-8. PMC: 505418. DOI: 10.1136/bjo.80.2.187. View

Pertwee R . Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed. 1999; 6 Suppl 3:12-5. DOI: 10.1159/000057150. View

Bianchi L, Monaldi F, Paolucci S, Iani C, Lacquaniti F . Quantitative analysis of the pendulum test: application to multiple sclerosis patients treated with botulinum toxin. Funct Neurol. 1999; 14(2):79-92. View

Urgosik D, Vymazal J, Vladyka V, Liscak R . Gamma knife treatment of trigeminal neuralgia: clinical and electrophysiological study. Stereotact Funct Neurosurg. 1998; 70 Suppl 1:200-9. DOI: 10.1159/000056423. View

de Mello M, Poyares D, Tufik S . Treatment of periodic leg movements with a dopaminergic agonist in subjects with total spinal cord lesions. Spinal Cord. 1999; 37(9):634-7. DOI: 10.1038/sj.sc.3100909. View

10.

Broggi G, Ferroli P, Franzini A, Servello D, Dones I . Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1999; 68(1):59-64. PMC: 1760596. DOI: 10.1136/jnnp.68.1.59. View

11.

Tranchant C, Bhatia K, Marsden C . Movement disorders in multiple sclerosis. Mov Disord. 1995; 10(4):418-23. DOI: 10.1002/mds.870100403. View

12.

Moulin D, Foley K, Ebers G . Pain syndromes in multiple sclerosis. Neurology. 1988; 38(12):1830-4. DOI: 10.1212/wnl.38.12.1830. View

13.

Pertwee R . Pharmacology of cannabinoid receptor ligands. Curr Med Chem. 1999; 6(8):635-64. View

14.

Kondziolka D, Perez B, Flickinger J, Habeck M, Lunsford L . Gamma knife radiosurgery for trigeminal neuralgia: results and expectations. Arch Neurol. 1998; 55(12):1524-9. DOI: 10.1001/archneur.55.12.1524. View

15.

Reder A, Arnason B . Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995; 45(6):1097-100. DOI: 10.1212/wnl.45.6.1097. View

16.

Gracies J, Nance P, Elovic E, McGuire J, Simpson D . Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl. 1997; 6:S92-120. View

17.

YOUNG R . Spasticity: a review. Neurology. 1994; 44(11 Suppl 9):S12-20. View

18.

Ramirez-Lassepas M, Tulloch J, Quinones M, Snyder B . Acute radicular pain as a presenting symptom in multiple sclerosis. Arch Neurol. 1992; 49(3):255-8. DOI: 10.1001/archneur.1992.00530270069020. View

19.

Stenager E, Knudsen L, Jensen K . Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand. 1991; 84(3):197-200. DOI: 10.1111/j.1600-0404.1991.tb04937.x. View

20.

Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Poewe W . Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000; 68(6):707-12. PMC: 1736956. DOI: 10.1136/jnnp.68.6.707. View